SNHG16 and neoplasm: Furthermore, miR‐23b‐3p in sorafenib‐treated Hep3B/So cells enlarged the tumor size more than Hep3B/So + So, Hep3B/So + si‐SNHG16 + So and Hep3B/So + si‐SNHG16 + inhibitor+So groups, suggesting that the inhibition of miR‐23b‐3p was able to significantly increase the tumor size.